Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study
| Autor: | S Walker, Christophe Leclercq, Bailleul C, Melissa Fitzgerald, Jean-Claude Daubert, Frieder Braunschweig, Stéphane Garrigue, Cecilia Linde, William J. McKenna, Jean-Claude Deharo, Thomas Lavergne, S. Rex, Serge Cazeau, Christine Alonso |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Pacemaker Artificial medicine.medical_specialty Time Factors Heart disease Cardiomyopathy Electrocardiography Internal medicine Atrial Fibrillation medicine Humans Single-Blind Method Sinus rhythm Aged Heart Failure Cross-Over Studies Exercise Tolerance Ejection fraction medicine.diagnostic_test business.industry Cardiac Pacing Artificial Atrial fibrillation Middle Aged medicine.disease Crossover study Hospitalization Case-Control Studies Heart failure Quality of Life Cardiology Female Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| Zdroj: | Journal of the American College of Cardiology. 40:111-118 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(02)01932-0 |
| Popis: | Objectives The main objective of this study was to assess if the benefits of biventricular (BiV) pacing observed during the crossover phase were sustained over 12 months. Background MUltisite STimulation In Cardiomyopathies (MUSTIC) is a randomized controlled study intended to evaluate the effects of BiV pacing in patients with New York Heart Association (NYHA) class III heart failure and intraventricular conduction delay. Methods Of 131 patients included, 42/67 in sinus rhythm (SR) and 33/64 in atrial fibrillation (AF) were followed up longitudinally at 9 and 12 months by 6-min walked distance, peak oxygen uptake (peak VO2), quality of life by the Minnesota score, NYHA class, echocardiography, and left ventricular ejection fraction by radionuclide technique. Results At 12 months, all SR and 88% of AF patients were programmed to BiV pacing. Compared with baseline, the 6-min walked distance increased by 20% (SR) (p = 0.0001) and 17% (AF) (p = 0.004); the peak VO2by 11% (SR) and 9% (AF); quality of life improved by 36% (SR) (p = 0.0001) and 32% (AF) (p = 0.002); NYHA class improved by 25% (SR) (p = 0.0001) and 27% (AF) (p = 0.0001). The ejection fraction improved by 5% (SR) and 4% (AF). Mitral regurgitation decreased by 45% (SR) and 50% (AF). Conclusions The clinical benefits of BiV pacing appeared to be significantly maintained over a 12-month follow-up period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|